Literature DB >> 28490423

Declining Trends of Cardiovascular-Renal Complications and Mortality in Type 2 Diabetes: The Hong Kong Diabetes Database.

Andrea O Y Luk1, Eric M T Hui2, Ming-Chuen Sin3, Chun-Yip Yeung4, Wing-Sun Chow4, Andrew Y Y Ho5, Hin-Fai Hung6, Eva Kan7, Chiu-Ming Ng7, Wing-Yee So8, Chi-Kin Yeung9, Kin-Sang Chan10, Kin-Wah Chan6, Pang-Fai Chan11, Shing-Chung Siu12, Sau-Cheung Tiu7, Vincent T F Yeung13, Juliana C N Chan14, Frank W K Chan15, Clement Cheung15, Ngai-Tseung Cheung15, Siu-Tung Ho14, Karen S L Lam16, Linda W L Yu15, David Chao11, Ip-Tim Lau9.   

Abstract

OBJECTIVE: Nationwide studies on secular trends of diabetes complications are not available in Asia. We examined changes in risk factor control and incidence of complications from diabetes and death in a large longitudinal cohort of Chinese adults with type 2 diabetes in Hong Kong. RESEARCH DESIGN AND METHODS: Between 1 January 2000 and 31 December 2012, 338,908 Chinese adults with type 2 diabetes underwent metabolic and complication assessment in 16 diabetes centers operated by Hong Kong Hospital Authority that provided care to a large majority of diagnosed patients. Patients were followed for incident acute myocardial infarction (AMI), stroke, end-stage renal disease (ESRD), and death until 31 December 2012. Risk factor levels between enrollment periods were compared. Incidence of clinical events, stratified by diabetes duration, was examined over time.
RESULTS: Incidence of complications from diabetes and death declined over the observation period in patients at varying disease duration. Among the high-risk group with diabetes for at least 15 years, crude incidence of AMI decreased from 8.7 to 5.8, stroke from 13.5 to 10.1, ESRD from 25.8 to 22.5, and death from 29.0 to 26.6 per 1,000 person-year between the periods 2000 to 2002 and 2010 to 2012. Improvements in levels of metabolic risk factors were detected. Proportion of patients achieving HbA1c <7.0% (53 mmol/mol) was increased from 32.9 to 50.0%, blood pressure ≤130/80 mmHg from 24.7 to 30.7%, and LDL cholesterol <2.6 mmol/L from 25.8 to 38.1%.
CONCLUSIONS: From this territory-wide Hong Kong Diabetes Database, we observed decreases in incidence of cardiovascular-renal complications and death and corresponding improvements in risk factor control over a 13-year period.
© 2017 by the American Diabetes Association.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28490423     DOI: 10.2337/dc16-2354

Source DB:  PubMed          Journal:  Diabetes Care        ISSN: 0149-5992            Impact factor:   19.112


  33 in total

Review 1.  Global trends in diabetes complications: a review of current evidence.

Authors:  Jessica L Harding; Meda E Pavkov; Dianna J Magliano; Jonathan E Shaw; Edward W Gregg
Journal:  Diabetologia       Date:  2018-08-31       Impact factor: 10.122

Review 2.  Aspects of Multicomponent Integrated Care Promote Sustained Improvement in Surrogate Clinical Outcomes: A Systematic Review and Meta-analysis.

Authors:  Lee Ling Lim; Eric S H Lau; Alice P S Kong; Melanie J Davies; Naomi S Levitt; Björn Eliasson; Carlos A Aguilar-Salinas; Guang Ning; Yutaka Seino; Wing Yee So; Margaret McGill; Graham D Ogle; Trevor J Orchard; Philip Clarke; Rury R Holman; Edward W Gregg; Juan José Gagliardino; Juliana C N Chan
Journal:  Diabetes Care       Date:  2018-06       Impact factor: 19.112

Review 3.  The Prevalence of Diabetic Microvascular Complications in China and the USA.

Authors:  Yu Kuei Lin; Bixia Gao; Lili Liu; Lynn Ang; Kara Mizokami-Stout; Rodica Pop-Busui; Luxia Zhang
Journal:  Curr Diab Rep       Date:  2021-04-09       Impact factor: 4.810

4.  Effectiveness of quality of care for patients with type 2 diabetes in China: findings from the Shanghai Integration Model (SIM).

Authors:  Chun Cai; Yuexing Liu; Yanyun Li; Yan Shi; Haidong Zou; Yuqian Bao; Yun Shen; Xin Cui; Chen Fu; Weiping Jia
Journal:  Front Med       Date:  2021-10-27       Impact factor: 4.592

5.  Eighteen-year trends in the management of patients with diabetes in the Shiga Diabetes Clinical Survey: overall trends and differences by age group.

Authors:  Itsuko Miyazawa; Hiroshi Maegawa; Aya Kadota; Takashi Nakamura; Makoto Konishi; Shinichi Ochi; Katsuyuki Miura; Motozumi Okamoto
Journal:  Diabetol Int       Date:  2022-02-17

6.  Improvement in Age at Mortality and Changes in Causes of Death in the Population with Diabetes: An Analysis of Data from the Korean National Health Insurance and Statistical Information Service, 2006 to 2018.

Authors:  Eugene Han; Sun Ok Song; Hye Soon Kim; Kang Ju Son; Sun Ha Jee; Bong-Soo Cha; Byung-Wan Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2022-06-29

7.  Prevalence of long-term complications in inpatients with diabetes mellitus in China: a nationwide tertiary hospital-based study.

Authors:  Yihao Liu; Xin Ning; Luyao Zhang; Jianyan Long; Ruiming Liang; Sui Peng; Haibo Wang; Yanbing Li; Wei Chen; Haipeng Xiao
Journal:  BMJ Open Diabetes Res Care       Date:  2022-05

8.  Secular trends in all-cause and cause-specific mortality rates in people with diabetes in Hong Kong, 2001-2016: a retrospective cohort study.

Authors:  Hongjiang Wu; Eric S H Lau; Ronald C W Ma; Alice P S Kong; Sarah H Wild; William Goggins; Elaine Chow; Wing-Yee So; Juliana C N Chan; Andrea O Y Luk
Journal:  Diabetologia       Date:  2020-01-16       Impact factor: 10.122

9.  Incidence and relative risk of renal replacement therapy in people with and without diabetes between 2002 and 2016 in a German region.

Authors:  Maria Narres; Heiner Claessen; Tatjana Kvitkina; Michael Koch; Lars Christian Rump; Thomas Weinreich; Andrea Icks
Journal:  Diabetologia       Date:  2019-12-21       Impact factor: 10.122

10.  Renal Replacement Therapy in People With and Without Diabetes in Germany, 2010-2016: An Analysis of More Than 25 Million Inhabitants.

Authors:  Heiner Claessen; Maria Narres; Tatjana Kvitkina; Adrian Wilk; Heiko Friedel; Christian Günster; Falk Hoffmann; Michael Koch; Karin Jandeleit-Dahm; Andrea Icks
Journal:  Diabetes Care       Date:  2021-05-04       Impact factor: 17.152

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.